Tigermed
泰格医药
Executive Summary
Tigermed is China's largest CRO with ~$900M revenue, providing clinical trial management services to multinational pharma companies. Founded by Xiaoping Ye in 2004, the company is publicly listed on Hong Kong Stock Exchange. While not formally designated under BIOSECURE, it faces congressional pressure and represents a significant compliance risk for US pharma partnerships given its core mainland China operations.
Structure: Tigermed operates through a Hong Kong-listed holding company structure with primary operations conducted through Hangzhou Tigermed Consulting on the mainland. The company appears to follow a standard Chinese corporate structure for overseas listings, though specific VIE arrangements are not detailed in available information.
Key People
| Name | Title | Education | Flags |
|---|---|---|---|
Xiaoping Ye 叶小平 | Founder & Chairman | MD, Zhejiang University |
Ownership & Shareholder Structure
Tigermed → AstraZeneca
Tigermed provides clinical trial management services to AstraZeneca in China.
Tigermed → Novartis
Tigermed provides clinical trial management services to Novartis in China.
Tigermed → Medicilon
Both Chinese CROs competing for multinational pharma clinical trial contracts.
Subsidiaries & Affiliates(1)
| Entity | Type | Jurisdiction | Scope | Flags | BIOSECURE |
|---|---|---|---|---|---|
Hangzhou Tigermed Consulting 杭州泰格医药科技股份有限公司 | operating | mainland china | Clinical trial management, regulatory affairs, pharmacovigilance. Largest Chinese CRO. | CDMO | DIRECT |
BIOSECURE Risk
Despite not being formally designated, Tigermed faces active congressional pressure and operates core CRO services from mainland China, creating direct BIOSECURE exposure
Key Exposures:
- •Clinical trial data handling in mainland China
- •Regulatory affairs services
- •Pharmacovigilance operations
- •Congressional scrutiny as Category B risk
Mitigation: No specific BIOSECURE mitigation measures identified in available information
BD Intelligence
Therapeutic Areas:
Recent Deals: No recent out-licensing deals recorded - company operates as service provider rather than asset developer
Approach: Approach with extreme caution due to BIOSECURE risks; consider alternative CRO providers or wait for regulatory clarity
Red Flags
- ⚠Congressional pressure under BIOSECURE Category B
- ⚠Core operations in mainland China create data security concerns
- ⚠Regulatory uncertainty could impact ongoing clinical trials
- ⚠No apparent BIOSECURE mitigation strategy
Quick Facts
- Key People
- 1
- Subsidiaries
- 1
- CDMO/CRO Subs
- 1
- Genomics Subs
- 0
- Direct BIOSECURE
- 1
- Corp Events
- 0
- Gov-Connected
- 0
- Clinical Trials
- 0
- Publications
- 0
- Drug Molecules
- 0
- Relationships
- 6
Sources & Methodology
Clinical trials data: ClinicalTrials.gov API v2 (0 trials linked to this entity)
SEC BIOSECURE filings: EDGAR EFTS full-text search (850+ filings from 230 companies)
Publications: Europe PMC API (0 publications indexed)
Drug molecules: ChEMBL database (European Bioinformatics Institute)
Financial data: East Money (东方财富) datacenter API / CNINFO (巨潮资讯网)
Corporate structure: HKEX annual reports, HKEX Disclosure of Interests
Executive profiles: Company official biographies, SEC filings, LinkedIn (where verified)
Data is collected from public sources and updated weekly. Corporate intelligence is verified by a native Mandarin-speaking analyst against Chinese-language primary sources including Tianyancha (天眼查), GSXT (国家企业信用信息公示系统), and CNINFO (巨潮资讯网). This is not financial or legal advice.